NAFLD and Diabetes: Two Sides of the Same Coin? Rationale for Gene-Based Personalized NAFLD Treatment
The prevalence of non-alcoholic fatty liver disease (NAFLD) has been increasing rapidly and at the forefront of worldwide concern. Characterized by excessive fat accumulation in the liver, NAFLD regularly coexists with metabolic disorders, including type 2 diabetes, obesity, and cardiovascular disea...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2019-08-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fphar.2019.00877/full |
| _version_ | 1818907528215396352 |
|---|---|
| author | Ming-Feng Xia Ming-Feng Xia Hua Bian Hua Bian Xin Gao Xin Gao |
| author_facet | Ming-Feng Xia Ming-Feng Xia Hua Bian Hua Bian Xin Gao Xin Gao |
| author_sort | Ming-Feng Xia |
| collection | DOAJ |
| description | The prevalence of non-alcoholic fatty liver disease (NAFLD) has been increasing rapidly and at the forefront of worldwide concern. Characterized by excessive fat accumulation in the liver, NAFLD regularly coexists with metabolic disorders, including type 2 diabetes, obesity, and cardiovascular disease. It has been well established that the presence of NAFLD increases the incidence of type 2 diabetes, while diabetes aggravates NAFLD to more severe forms of steatohepatitis, cirrhosis, and hepatocellular carcinoma. However, recent progress on the genotype/phenotype relationships in NAFLD patients indicates the development of NAFLD with a relative conservation of glucose metabolism in individuals with specific gene variants, such as the patatin-like phospholipase domain-containing 3 (PNPLA3) and transmembrane 6 superfamily member 2 protein (TM6SF2) variants. This review will focus on the clinical and pathophysiological connections between NAFLD and type 2 diabetes and will also discuss a disproportionate progression of NAFLD and diabetes, and the different responses to lifestyle and drug intervention in NAFLD patients with specific gene variants that may give insight into personalized treatment for NAFLD. |
| first_indexed | 2024-12-19T21:56:33Z |
| format | Article |
| id | doaj.art-65a793be5a2a42d48251330bafd204f4 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-12-19T21:56:33Z |
| publishDate | 2019-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-65a793be5a2a42d48251330bafd204f42022-12-21T20:04:15ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122019-08-011010.3389/fphar.2019.00877464931NAFLD and Diabetes: Two Sides of the Same Coin? Rationale for Gene-Based Personalized NAFLD TreatmentMing-Feng Xia0Ming-Feng Xia1Hua Bian2Hua Bian3Xin Gao4Xin Gao5Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, ChinaFudan Institute for Metabolic Diseases, Fudan University, Shanghai, ChinaDepartment of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, ChinaFudan Institute for Metabolic Diseases, Fudan University, Shanghai, ChinaDepartment of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, ChinaFudan Institute for Metabolic Diseases, Fudan University, Shanghai, ChinaThe prevalence of non-alcoholic fatty liver disease (NAFLD) has been increasing rapidly and at the forefront of worldwide concern. Characterized by excessive fat accumulation in the liver, NAFLD regularly coexists with metabolic disorders, including type 2 diabetes, obesity, and cardiovascular disease. It has been well established that the presence of NAFLD increases the incidence of type 2 diabetes, while diabetes aggravates NAFLD to more severe forms of steatohepatitis, cirrhosis, and hepatocellular carcinoma. However, recent progress on the genotype/phenotype relationships in NAFLD patients indicates the development of NAFLD with a relative conservation of glucose metabolism in individuals with specific gene variants, such as the patatin-like phospholipase domain-containing 3 (PNPLA3) and transmembrane 6 superfamily member 2 protein (TM6SF2) variants. This review will focus on the clinical and pathophysiological connections between NAFLD and type 2 diabetes and will also discuss a disproportionate progression of NAFLD and diabetes, and the different responses to lifestyle and drug intervention in NAFLD patients with specific gene variants that may give insight into personalized treatment for NAFLD.https://www.frontiersin.org/article/10.3389/fphar.2019.00877/fullnon-alcoholic fatty liver diseasediabetesgene variantpathogenesispersonalized treatment |
| spellingShingle | Ming-Feng Xia Ming-Feng Xia Hua Bian Hua Bian Xin Gao Xin Gao NAFLD and Diabetes: Two Sides of the Same Coin? Rationale for Gene-Based Personalized NAFLD Treatment Frontiers in Pharmacology non-alcoholic fatty liver disease diabetes gene variant pathogenesis personalized treatment |
| title | NAFLD and Diabetes: Two Sides of the Same Coin? Rationale for Gene-Based Personalized NAFLD Treatment |
| title_full | NAFLD and Diabetes: Two Sides of the Same Coin? Rationale for Gene-Based Personalized NAFLD Treatment |
| title_fullStr | NAFLD and Diabetes: Two Sides of the Same Coin? Rationale for Gene-Based Personalized NAFLD Treatment |
| title_full_unstemmed | NAFLD and Diabetes: Two Sides of the Same Coin? Rationale for Gene-Based Personalized NAFLD Treatment |
| title_short | NAFLD and Diabetes: Two Sides of the Same Coin? Rationale for Gene-Based Personalized NAFLD Treatment |
| title_sort | nafld and diabetes two sides of the same coin rationale for gene based personalized nafld treatment |
| topic | non-alcoholic fatty liver disease diabetes gene variant pathogenesis personalized treatment |
| url | https://www.frontiersin.org/article/10.3389/fphar.2019.00877/full |
| work_keys_str_mv | AT mingfengxia nafldanddiabetestwosidesofthesamecoinrationaleforgenebasedpersonalizednafldtreatment AT mingfengxia nafldanddiabetestwosidesofthesamecoinrationaleforgenebasedpersonalizednafldtreatment AT huabian nafldanddiabetestwosidesofthesamecoinrationaleforgenebasedpersonalizednafldtreatment AT huabian nafldanddiabetestwosidesofthesamecoinrationaleforgenebasedpersonalizednafldtreatment AT xingao nafldanddiabetestwosidesofthesamecoinrationaleforgenebasedpersonalizednafldtreatment AT xingao nafldanddiabetestwosidesofthesamecoinrationaleforgenebasedpersonalizednafldtreatment |